262 related articles for article (PubMed ID: 33126605)
1. Associations of
Chang JH; Lai TC; Yang PJ; Shih PC; Yang YC; Lee KL; Liu TC; Tsao TC; Yang SF; Chien MH
Int J Mol Sci; 2020 Oct; 21(21):. PubMed ID: 33126605
[TBL] [Abstract][Full Text] [Related]
2. Potential Impacts of
Lee KL; Lai TC; Wang YC; Shih PC; Yang YC; Tsao TC; Liu TC; Wen YC; Chang LC; Yang SF; Chien MH
Genes (Basel); 2021 Mar; 12(3):. PubMed ID: 33802737
[TBL] [Abstract][Full Text] [Related]
3. Polymorphisms and Plasma Levels of Tissue Inhibitor of Metalloproteinase-3: Impact on Genetic Susceptibility and Clinical Outcome of Oral Cancer.
Su CW; Huang YW; Chen MK; Su SC; Yang SF; Lin CW
Medicine (Baltimore); 2015 Nov; 94(46):e2092. PubMed ID: 26579821
[TBL] [Abstract][Full Text] [Related]
4. The Relationship between Long Noncoding RNA H19 Polymorphism and the Epidermal Growth Factor Receptor Phenotypes on the Clinicopathological Characteristics of Lung Adenocarcinoma.
Wang YC; Tsao SM; Li YT; Lee CY; Tsao TC; Hsieh MJ; Yang SF
Int J Environ Res Public Health; 2021 Mar; 18(6):. PubMed ID: 33799753
[TBL] [Abstract][Full Text] [Related]
5. Computed Tomography-Based Radiomics Signature: A Potential Indicator of Epidermal Growth Factor Receptor Mutation in Pulmonary Adenocarcinoma Appearing as a Subsolid Nodule.
Yang X; Dong X; Wang J; Li W; Gu Z; Gao D; Zhong N; Guan Y
Oncologist; 2019 Nov; 24(11):e1156-e1164. PubMed ID: 30936378
[TBL] [Abstract][Full Text] [Related]
6. Impact of Aurora Kinase A Polymorphism and Epithelial Growth Factor Receptor Mutations on the Clinicopathological Characteristics of Lung Adenocarcinoma.
Yang PJ; Hsieh MJ; Lee CI; Yen CH; Wang HL; Chiang WL; Liu TC; Tsao TC; Lee CY; Yang SF
Int J Environ Res Public Health; 2020 Oct; 17(19):. PubMed ID: 33050100
[TBL] [Abstract][Full Text] [Related]
7. Frequent DYRK2 gene amplification in micropapillary element of lung adenocarcinoma - an implication in progression in EGFR-mutated lung adenocarcinoma.
Koike C; Okudela K; Matsumura M; Mitsui H; Suzuki T; Arai H; Kataoka T; Ishikawa Y; Umeda S; Tateishi Y; Ohashi K
Histol Histopathol; 2021 Mar; 36(3):305-315. PubMed ID: 33368138
[TBL] [Abstract][Full Text] [Related]
8. Risk of lung adenocarcinoma from smoking and radiation arises in distinct molecular pathways.
Castelletti N; Kaiser JC; Simonetto C; Furukawa K; Küchenhoff H; Stathopoulos GT
Carcinogenesis; 2019 Oct; 40(10):1240-1250. PubMed ID: 30915466
[TBL] [Abstract][Full Text] [Related]
9. Impact of Clinicopathological Characteristics and Tissue Inhibitor of Metalloproteinase-3 Polymorphism Rs9619311 on Biochemical Recurrence in Taiwanese Patients with Prostate Cancer.
Hsieh CY; Lin CY; Wang SS; Chou YE; Chien MH; Wen YC; Hsieh MJ; Yang SF
Int J Environ Res Public Health; 2022 Dec; 20(1):. PubMed ID: 36612628
[TBL] [Abstract][Full Text] [Related]
10. Impact of clinicopathologic features on leptomeningeal metastasis from lung adenocarcinoma and treatment efficacy with epidermal growth factor receptor tyrosine kinase inhibitor.
Kwon BS; Cho YH; Yoon SK; Lee DH; Kim SW; Kwon DH; Lee JC; Choi CM
Thorac Cancer; 2020 Feb; 11(2):436-442. PubMed ID: 31910497
[TBL] [Abstract][Full Text] [Related]
11. Clinical significance of serum EGFR gene mutation and serum tumor markers in predicting tyrosine kinase inhibitor efficacy in lung adenocarcinoma.
Feng LX; Wang J; Yu Z; Song SA; Zhai WX; Dong SH; Yu HS; Zhang Y
Clin Transl Oncol; 2019 Aug; 21(8):1005-1013. PubMed ID: 30637712
[TBL] [Abstract][Full Text] [Related]
12. Intense Expression of EGFR L858R Characterizes the Micropapillary Component and L858R Is Associated with the Risk of Recurrence in pN0M0 Lung Adenocarcinoma with the Micropapillary Component.
Kishi N; Ito M; Miyata Y; Kanai A; Handa Y; Tsutani Y; Kushitani K; Takeshima Y; Okada M
Ann Surg Oncol; 2020 Mar; 27(3):945-955. PubMed ID: 31732945
[TBL] [Abstract][Full Text] [Related]
13. Impact of tissue inhibitor of metalloproteinases-3 genetic variants on clinicopathological characteristics of urothelial cell carcinoma.
Weng WC; Hsieh MH; Chiou HL; Lee CY; Tang CH; Chang LC; Wang SS; Yang SF
J Cancer; 2023; 14(3):360-366. PubMed ID: 36860920
[TBL] [Abstract][Full Text] [Related]
14. Uncommon EGFR mutations associate with lower incidence of T790M mutation after EGFR-TKI treatment in patients with advanced NSCLC.
Yang S; Mao S; Li X; Zhao C; Liu Q; Yu X; Wang Y; Liu Y; Pan Y; Wang C; Gao G; Li W; Xiong A; Chen B; Sun H; He Y; Wu F; Chen X; Su C; Ren S; Zhou C
Lung Cancer; 2020 Jan; 139():133-139. PubMed ID: 31786475
[TBL] [Abstract][Full Text] [Related]
15. Differences in Immunological Landscape between
Luo JW; Guo YH; Wu FY; Li XF; Sun XC; Wang JL; Zhou CC
Dis Markers; 2021; 2021():3776854. PubMed ID: 34484468
[TBL] [Abstract][Full Text] [Related]
16. A Histopathological Feature of EGFR-Mutated Lung Adenocarcinomas with Highly Malignant Potential - An Implication of Micropapillary Element.
Matsumura M; Okudela K; Kojima Y; Umeda S; Tateishi Y; Sekine A; Arai H; Woo T; Tajiri M; Ohashi K
PLoS One; 2016; 11(11):e0166795. PubMed ID: 27861549
[TBL] [Abstract][Full Text] [Related]
17. Effect of tissue inhibitor of metalloproteinases-3 genetics polymorphism on clinicopathological characteristics of uterine cervical cancer patients in Taiwan.
Chung JF; Chen CL; Nassef Y; Shiu BH; Wang CH; Kuo FH; Hsiao YH; Yang SF; Wang PH
Int J Med Sci; 2022; 19(6):1013-1022. PubMed ID: 35813301
[TBL] [Abstract][Full Text] [Related]
18. EGFR and KRAS Mutations in Lung Parenchyma of Subjects With EGFR/KRAS Wild-Type Lung Adenocarcinoma.
Chalela R; González-García JG; Khilzi K; Curull V; Sánchez-Font A; Longarón R; Rodrigo-Calvo MT; Martín-Ontiyuelo C; Gea J; Bellosillo B
Pathol Oncol Res; 2021; 27():598292. PubMed ID: 34257550
[TBL] [Abstract][Full Text] [Related]
19. Unique microRNAs in lung adenocarcinoma groups according to major TKI sensitive EGFR mutation status.
Pak MG; Lee CH; Lee WJ; Shin DH; Roh MS
Diagn Pathol; 2015 Jul; 10():99. PubMed ID: 26170125
[TBL] [Abstract][Full Text] [Related]
20. Specific expression of MUC21 in micropapillary elements of lung adenocarcinomas - Implications for the progression of EGFR-mutated lung adenocarcinomas.
Matsumura M; Okudela K; Nakashima Y; Mitsui H; Denda-Nagai K; Suzuki T; Arai H; Umeda S; Tateishi Y; Koike C; Kataoka T; Irimura T; Ohashi K
PLoS One; 2019; 14(4):e0215237. PubMed ID: 30973916
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
